Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Patients in Europe with the ultra rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) are a step closer to getting the first therapeutic specifically indicated for treating the disease, after Ablynx filed for approval of caplacizumab.